BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22467867)

  • 21. Regulation of nucleolar signalling to p53 through NEDDylation of L11.
    Sundqvist A; Liu G; Mirsaliotis A; Xirodimas DP
    EMBO Rep; 2009 Oct; 10(10):1132-9. PubMed ID: 19713960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.
    Tolbert D; Lu X; Yin C; Tantama M; Van Dyke T
    Mol Cell Biol; 2002 Jan; 22(1):370-7. PubMed ID: 11739748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ARF tumor suppression in the nucleolus.
    Maggi LB; Winkeler CL; Miceli AP; Apicelli AJ; Brady SN; Kuchenreuther MJ; Weber JD
    Biochim Biophys Acta; 2014 Jun; 1842(6):831-9. PubMed ID: 24525025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perturbation of RNA Polymerase I transcription machinery by ablation of HEATR1 triggers the RPL5/RPL11-MDM2-p53 ribosome biogenesis stress checkpoint pathway in human cells.
    Turi Z; Senkyrikova M; Mistrik M; Bartek J; Moudry P
    Cell Cycle; 2018; 17(1):92-101. PubMed ID: 29143558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
    Lin AW; Lowe SW
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction.
    Sun XX; Dai MS; Lu H
    J Biol Chem; 2007 Mar; 282(11):8052-9. PubMed ID: 17242401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation.
    Sashida G; Liu Y; Elf S; Miyata Y; Ohyashiki K; Izumi M; Menendez S; Nimer SD
    Mol Cell Biol; 2009 Jul; 29(13):3687-99. PubMed ID: 19380490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ARF function does not require p53 stabilization or Mdm2 relocalization.
    Korgaonkar C; Zhao L; Modestou M; Quelle DE
    Mol Cell Biol; 2002 Jan; 22(1):196-206. PubMed ID: 11739734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11.
    Sun XX; Dai MS; Lu H
    J Biol Chem; 2008 May; 283(18):12387-92. PubMed ID: 18305114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MdmX inhibits ARF mediated Mdm2 sumoylation.
    Ghosh M; Weghorst K; Berberich SJ
    Cell Cycle; 2005 Apr; 4(4):604-8. PubMed ID: 15876864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HEY1 functions are regulated by its phosphorylation at Ser-68.
    López-Mateo I; Arruabarrena-Aristorena A; Artaza-Irigaray C; López JA; Calvo E; Belandia B
    Biosci Rep; 2016 Jul; 36(3):. PubMed ID: 27129302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
    Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
    Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53.
    Eischen CM; Boyd K
    PLoS One; 2012; 7(9):e46148. PubMed ID: 23029416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
    Zhang Y; Xiong Y; Yarbrough WG
    Cell; 1998 Mar; 92(6):725-34. PubMed ID: 9529249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53.
    Zhang Y; Xiong Y
    Mol Cell; 1999 May; 3(5):579-91. PubMed ID: 10360174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SPIN1 promotes tumorigenesis by blocking the uL18 (universal large ribosomal subunit protein 18)-MDM2-p53 pathway in human cancer.
    Fang Z; Cao B; Liao JM; Deng J; Plummer KD; Liao P; Liu T; Zhang W; Zhang K; Li L; Margolin D; Zeng SX; Xiong J; Lu H
    Elife; 2018 Mar; 7():. PubMed ID: 29547122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribosomal protein L4 is a novel regulator of the MDM2-p53 loop.
    He X; Li Y; Dai MS; Sun XX
    Oncotarget; 2016 Mar; 7(13):16217-26. PubMed ID: 26908445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels.
    Goudarzi KM; Nistér M; Lindström MS
    Cancer Biol Ther; 2014; 15(11):1499-514. PubMed ID: 25482947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing.
    Sugimoto M; Kuo ML; Roussel MF; Sherr CJ
    Mol Cell; 2003 Feb; 11(2):415-24. PubMed ID: 12620229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ribosomal protein S2 interplays with MDM2 to induce p53.
    Cho J; Park J; Shin SC; Kim JH; Kim EE; Song EJ
    Biochem Biophys Res Commun; 2020 Mar; 523(2):542-547. PubMed ID: 31928715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.